Journal article

Computed Tomographic Perfusion Predicts Poor Outcomes in a Randomized Trial of Endovascular Therapy

Robert Wannamaker, Taurian Guinand, Bijoy K Menon, Andrew Demchuk, Mayank Goyal, Donald Frei, Aditya Bharatha, Tudor G Jovin, Jai Shankar, Timo Krings, Blaise Baxter, Christine Holmstedt, Richard Swartz, Dar Dowlatshahi, Richard Chan, Donatella Tampieri, Hana Choe, Paul Burns, Nina Gentile, Jeremy Rempel Show all

Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018

Grants

Funding Acknowledgements

Dr Butcher received salary support from Canada Research Chairs program and Heart and Stroke Foundation of Alberta, Northwest Territories and Nunavut (NWT and NU). T. Guinand received salary support from Quality Improvement and Clinical Research Alberta Stroke Program. Dr Baxter received personal fees from Covidien, Penumbra, Stryker Neurovascular, Silk Road Medical, Reverse Medical, Rapid Medical, Concentric Medical, and Codman Medical and has a patent related to a neuronal protection system (US 8 622 992). Dr Demchuk received personal fees and grant support from Covidien. Dr Frei received personal fees from Covidien and Penumbra outside the submitted work. Dr Goyal received grant support and personal fees from Covidien pending patent related to systems and methods for diagnosing strokes (WO 2014/036638) and licensed to GE Healthcare. Dr Hill received grant support from Covidien, the Calgary Stroke Program, the Hotchkiss Brain Institute, the University of Calgary, the Heart and Stroke Foundation of Alberta, NWT, NU, and Alberta Innovates Health Solutions, personal fees from Merck, and nonfinancial support from Hoffmann-La Roche Canada, has a pending patent related to systems and methods for assisting in decision making and triaging for acute stroke patients (US patent office number 62/086,077), and holds stock ownership in Calgary Scientific, Inc. Dr Holmstedt received grant support from National Institutes of Health (NIH)/National Institute of General Medical Sciences (NIGMS), AstraZeneca, Genentech, Penumbra, the NIH/National Institute of Neurological Disorders and Stroke (NINDS), Remedy, Edwards Lifesciences LLC, the South Carolina Clinical and Translational Research Institute/Clinical Translational Science Award, and Stryker, grant support and personal fees from Covidien, and personal fees from CE Outcomes, Inc. Dr Jovin acts as an investor/advisor at Route 92, Anaconda, FreeOX Biotech, Blockade Medical, Silk Road and as a consultant at Cerenovus, Stryker Neurovascular. The other authors report no conflicts.